Skip to Main Content

WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want Congress to take a deeper look at how Biogen’s controversial and pricey new Alzheimer’s drug, Aduhelm, will affect the Medicare program, they wrote in a letter Wednesday.

The bipartisan duo is pressing the Senate Finance Committee to take on “the vexing new questions and challenges that approval raises for the Medicare program and other health programs” the panel oversees, they wrote.


Experts predict the drug could dramatically increase Medicare spending. If even just 500,000 of the 6.2 million seniors currently living with Alzheimer’s began taking Aduhelm, Medicare drug spending would balloon by $29 billion in one year, according to an estimate from the nonpartisan Kaiser Family Foundation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.